Showing 241-245 of 259 resources:
Big Data: Hoax or Hero in Real-World Evidence for Cardiovascular and Metabolic Diseases?

On this webinar, Dr. Richard Gliklich, CEO of OM1, discussed the evolving role of big data and cognitive computing in generating real-world evidence for cardiovascular and metabolic diseases. This session explored how innovative methodologies and technologies can be applied to support safety, value, and commercial strategies. Topics covered included: New real-world evidence methodologies and approaches[…]

From Big Data to Measurable Outcomes: Aligning Stakeholder Needs for Value Based Contracts

A heightened focus on value is driving efforts across health care to improve outcomes and reduce costs. For pharmaceutical companies, this focus translates into a shift away from traditional payment models to more outcomes-based, risk sharing agreements. In many ways, these agreements present the opportunity to better align interests across health care’s stakeholders. However, they[…]

Becker’s Spine, Orthopedic, and Spine Conference – Chicago

On June 22-23, we were at the annual Becker’s Spine, Ortho and Pain conference in Chicago and talking about how we’re demonstrating that measured, precise and pre-emptive care generates real ROI. Interested in learning more or furthering our discussions? Contact us at info@om1.com.

From Data to Innovative Models: Reducing Risks and Improving Joint Replacement Outcomes

At the forefront of a growing movement towards value-based care, orthopaedic surgeons are facing increasing pressure to make better decisions based on outcomes; to assume greater risk for the cost of joint replacement patient care; and to reduce overall costs while demonstrating quality improvement. Join us for a webinar addressing emerging initiatives, technologies and best[…]

Getting Outcomes Measures to Sing in Harmony Not an Easy Task

by Joyce Frieden, News Editor, MedPage Today, April 28, 2017 WASHINGTON — Measuring outcomes for heart disease treatment in the general population won’t do much good if researchers can’t agree on a single definition of a particular disease or on which outcomes are worth measuring. That’s why a group of interested organizations is developing a common[…]